Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a prominent player in the biotechnology sector, has announced the scheduled release of its first quarter 2026 financial results along with a business update. The report is set to be disclosed on May 12, 2026, post the closure of U.S. financial markets. Following the release, Lineage management will host a conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on the same day to discuss the financial results and provide insights into the company's strategic direction.

2. Conference Call Details

For those interested in participating, the conference call can be accessed by dialing (800) 715-9871 from the U.S. and Canada, with the request to join the "Lineage Cell Therapeutics Call" using conference ID 9229676. Additionally, the call will be available via live webcast in the Investors section of Lineage's official website. A replay of the webcast will be accessible for 30 days following the event, and a telephone replay will be available until May 19, 2026, at (800) 770-2030.

3. About Lineage Cell Therapeutics

Founded on innovative research, Lineage Cell Therapeutics is at the forefront of developing “off-the-shelf” allogeneic cell therapies aimed at addressing serious medical conditions. The company’s proprietary platform, AlloSCOPE™ (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), underpins its commitment to delivering specialized human cells that can effectively mimic natural cells in the body.

Lineage's current pipeline showcases a diverse range of therapies in various stages of development:

OpRegen®: A retinal pigment epithelial cell therapy currently in Phase 2a trials under collaboration with Roche and Genentech, targeting geographic atrophy associated with age-related macular degeneration.

OPC1: This oligodendrocyte progenitor cell therapy is in Phase 1/2a trials, focusing on spinal cord injury treatment.

ReSonance™ (ANP1): An auditory neuronal progenitor cell therapy in preclinical development, in collaboration with William Demant Invest A/S, intended for addressing auditory neuropathy.

PNC1: A research initiative exploring photoreceptor neural cell therapy for the treatment of vision loss due to dysfunction or damage.

RND1: This project is evaluating a novel hypoimmune induced pluripotent stem cell line under a gene editing partnership.

ILT1: Focused on large-scale production of undifferentiated pluripotent cells, with potential implications for treating Type 1 Diabetes.

COR1: A preclinical initiative aimed at developing a cell therapy for corneal endothelial disease.

4. Future Outlook

As Lineage prepares to unveil its quarterly financial results, stakeholders and investors are keenly awaiting insights that could shape the company’s trajectory in the rapidly evolving biotechnology landscape. The upcoming conference call is expected to shed light on the company’s operational strategies and financial health, especially given the significant developmental challenges associated with novel cell therapies.

In a sector characterized by innovation and high risk, the outcomes of Lineage’s ongoing projects and partnerships could play a crucial role in determining its market position and growth potential in the coming years. Investors and analysts alike will be watching closely for updates that could signal Lineage’s advancements in therapeutic development, regulatory approvals, and overall strategic initiatives.

Original press release